Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy

References

• Manusow D, Weinerman B H. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267–269
   PubMed Web of Science ®Google Scholar
• Greene M H, Hoover R N, Fraumeni J F, Jr. Subsequent cancer in patients with chronic lymphocytic leukemia: a possible immunologic mechanism. J Natl Cancer Inst 1978; 61: 337–340
   PubMed Web of Science ®Google Scholar
• Richter M N. Generalized reticular cell sarcoma of lymph nodes associated with lymphocytic leukemia. Am J Pathol 1928; 4: 285–291
   PubMedGoogle Scholar
• Giles F J, O'Brien S M, Keating M J. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998; 25: 117–125
   PubMed Web of Science ®Google Scholar
• Davis J W, Weiss N S, Armstrong B K. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1987; 78: 91–94
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–1511
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Hankey B F, Fraumeni J F, Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422–1427
   PubMed Web of Science ®Google Scholar
• Hisada M, Biggar R J, Greene M H, Fraumeni J F, Jr, Travis L B. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979–1981
   PubMed Web of Science ®Google Scholar
• Cheson B D, Vena D A, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for Chronic Lymphoid Leukemia. J Clin Oncol 1999; 17: 2454–2460
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Delannoy A, Foremans W, Ferrant A, Michaux L. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′-deoxyadenosine treatment. Leuk Lymphoma 2001; 40: 541–550
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski J Z, Gora-Tibor J, Kaznicki M, Konopka L, Ceglarek B, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia treated with cladribine. Eur J Cancer 2004; 40: 383–389
   PubMed Web of Science ®Google Scholar
• Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma 2004; 46: 49–54
   Web of Science ®Google Scholar
• Sawitsky A, Rai K R, Glidwell O, Silver R T. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–1059
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Fools J, Hamblin T J. CLL trials in the United Kingdom: MRC trials 1, 2 and 3. Leuk Lymphoma 1991; 5(Suppl 4)105–111
   Web of Science ®Google Scholar
• Jaksic B, Brugiatelli M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL – IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988; 30: 437–442
   PubMedGoogle Scholar
• Kempin S, Lee B J, Thaler H T, Koziner B, Hecht S, Gee T, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (Vincristine, BCNU, Cyclophosphamide, Melphalan and Prednisone). Blood 1982; 60: 1110–1121
   PubMed Web of Science ®Google Scholar
• Boussiotis V A, Panayotidis P G, Pangalis G A. Prolonged intermittent chlorambucil administration in B-chronic lymphocytic leukemia: experience from a single hematology unit. Leuk Lymphoma 1991; 5(Suppl 5)113–117
   Web of Science ®Google Scholar
• Angelopoulou M, Poziopoulos C, Boussiotis V A, Kontopidou F, Pangalis G A. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to substain response. Leuk Lymphoma 1996; 21: 321–324
   PubMed Web of Science ®Google Scholar
• Kauppi M J, Savolainen H A, Anttila V J, Isomaki H A. Increased risk of leukemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paedatr 1996; 85: 248–250
   PubMed Web of Science ®Google Scholar
• Dedrick R L, Morrison P F. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 1992; 52: 2464–2467
   PubMed Web of Science ®Google Scholar
• Patapanian H, Graham S, Sambrook P M, Browne C D, Champion G D, Cohen M L, et al. The oncogenecity of chlorambucil in reumatoid arthritis. Br J Rheumatol 1988; 27: 44–47
   PubMedGoogle Scholar
• Palmer R G, Denman A M. Malignancies induced by chlorambucil. Cancer Treat Rev 1984; 11: 121–129
   PubMed Web of Science ®Google Scholar
• Berk P D, Goldberg J D, Silverstein M N, Weinfeld A, Donovan P B, Ellis J T, et al. Increased incidence of acute leukemia in polycitemia vera associated with clorambucil therapy. N Engl J Med 1981; 304: 441–447
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennet J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternak B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, Chastan C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Jaksic B, Vitale B. Total tumor mass score (TTM): a new parameter in chronic lymphocytic leukemia. Br J Haematol 1981; 49: 405–413
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Frisch M, Storm H H, Glimelius B, Pedersen J B, Melbye M. Non melanoma skin cancer may be a marker of poor prognosis in patients with non Hodgkin's lymphoma. Int J Cancer 2000; 85: 639–642
   PubMed Web of Science ®Google Scholar
• Weimar V M, Ceilley R I, Goeken J A. Aggressive biologic behaviour of basal and squamous-cell cancer in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma. J Dermatol Surg Oncol 1979; 5: 609–614
   PubMedGoogle Scholar
• Mehrany K, Byrd D R, Roenigh R K, Weenig R H, Phillips P K, Nguyen T H, et al. Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic lymphocytic leukemia and solid-organ transplantation. Dermatol Surg 2003; 29: 19–134
   Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Robertson L E, Estey E, Kantarijan H, Koller C, O'Brien S, Brown B, et al. Therapy-related leukemia and myelodisplastic syndrome in chronic lymphocytic leukemia. Leukemia 1994; 8: 2047–2051
   PubMed Web of Science ®Google Scholar
• Zarrabi M H, Grunwald H W, Rosner F. Chronic lymphocytic leukemia terminating in acute leukemia. Arch Int Med 1977; 137: 1059–1064
   PubMed Web of Science ®Google Scholar
• Orchard J A, Bolam S, Oscier D G. Association of myelodisplastic changes with purine analogues. Br J Haematol 1998; 100: 677–679
   PubMed Web of Science ®Google Scholar
• Morrison V A, Rai K R, Peterson B L, Kaliz J E, Elias L, Appelbaum F R, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. J Clin Oncol 2002; 20: 3878–3884
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leucemia. Blood 1999; 94: 2836–2843
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarijan H, Beran M, Smith T, Koller C, Estey E, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700
   PubMed Web of Science ®Google Scholar
• Hochster H S, Oken M M, Winter J N, Gordon L I, Raphael B G, Bennett J M, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low grade lymphoma: Results and long-term follow-up. A report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000; 18: 987–994
   PubMed Web of Science ®Google Scholar
• O'Brien S M, Kantarjian H M, Cortes J, Beran M, Koller C A, Giles F J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420
   PubMed Web of Science ®Google Scholar
• Pederson-Bjergaard J, Andersen M K. Therapy-related myelodysplasia and acute myeloid leukemia risk and chromosome abnormalities. ASCO Publications, AlexandriaUSA 2001; 566–577
   Google Scholar